Synthesis and antitumor activity of 1-mesityl-3-(2-naphthoylmethano)-1H-imidazolium bromide

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 6, 2010, Pages 1844-1847

  Zeng, Xianghui ^a   Yang, Xiaodong ^a   Zhang, Yanli ^b   Qing, Chen ^b   Zhang, Hongbin ^a  

^a YUNNAN UNIVERSITY   (China)

^b KUNMING MEDICAL UNIVERSITY   (China)

Author keywords

Antitumor activity; Apoptosis; Cell cycle; MNIB

Indexed keywords

1 MESITYL 3 (2 NAPHTHOYLMETHANO) 1H IMIDAZOLIUM BROMIDE; ANTINEOPLASTIC AGENT; CISPLATIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL STRAIN A549; CELL STRAIN AGZY; CELL STRAIN EJ; CELL STRAIN HEP 2; CELL STRAIN HEPG2; CELL STRAIN K562; CELL STRAIN RAJI; CELL STRAIN SMMC 7721; CONTROLLED STUDY; DRUG MEGADOSE; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; TUMOR GROWTH; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; G1 PHASE; HUMANS; IMIDAZOLES; MICE; NAPHTHALENES;

EID: 77549085129     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.01.163     Document Type: Article

References (18)

1. Cui B., Zheng B.L., He K., and Zheng Q.Y. J. Nat. Prod. 66 (2003) 1101
2. Vik A., Hedner E., Charnock C., Tangen L.W., Samuelsen Ø., Larsson R., Bohlinb L., and Gundersen L.L. Bioorg. Med. Chem. 15 (2007) 4016
3. Demberelnyamba D., Kim K.S., Choi S., Park S.Y., Lee H., Kim C.J., and Yoo I.D. Bioorg. Med. Chem. 12 (2004) 853
4. Pernak J., Skrzypzzak A., Kucharski S., and Krysinski J. Arch. Pharm. 317 (1984) 430
5. Fortuna C.G., Barresi V., Berellini G., and Musumarra G. Bioorg. Med. Chem. 16 (2008) 4150
6. Ballistreri F.P., Barresi V., Benedetti P., Caltabiano G., Fortuna C.G., Longo M.L., and Musumarraa G. Bioorg. Med. Chem. 12 (2004) 1689
7. Miyachi H., Kiyota H., and Segawa M. Bioorg. Med. Chem. Lett. 9 (1999) 3003
8. Iizuka, K.; Kamijo, T.; Yamamoto, R.; Harada, H. U.S. Patent 4, 461,905, 1984.
9. Haugwitz, R. D.; Narayanan, V. L. U.S. Patent 3,852,301, 1974.
10. Lis R., Morgan Jr. T.K., DeVita R.J., Davey D.D., Lumman Jr. W.C., Wohl R.A., Diamond J., Wong S.S., and Sullivan M.E. J. Med. Chem. 30 (1987) 696
11. Li Q.L., Huang J., Wang Q., Jiang N., Xia C.Q., Lin H.H., Wu J., and Yu X.Q. Bioorg. Med. Chem. 14 (2006) 4151
12. Yang X.-D., Zeng X.-H., Zhang Y.-L., Qing C., Song W.-J., Li L., and Zhang H.-B. Bioorg. Med. Chem. Lett. 19 (2009) 1892
13. Liu J.P., Chen J.B., Zhao J.F., Zhao Y.H., Li L., and Zhang H.B. Synthesis (2003) 2661
14. 2O 434.0994, found 434.0992.
15. 2 in RPMI 1640 medium supplemented with 10% fetal serum and dispersed in replicate 96-well plates. Compounds were then added. After 48 h exposure to the compounds, cells viability were determined by the [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] (MTT) cytotoxicity assay by measuring the absorbance at 570 nm with a microplate spectrophotometer. Each test was performed in triplicate.
16. 6/mL) treated with or without varying concentrations of MNIB (2, 10 μg/mL) for 24 h were resuspended in 100 μL of binding buffer. Afterwards, cells were stained with 5 μL Annexin V-FITC solution and 10 μL PI solution for 15 min at room temperature in the dark. Then the samples were diluted with 300 μL of binding buffer and analyzed by flow cytometry using the FACScalibur (Becton-Dickinson, San Jose, CA).
17. 5 cells) and treated with 100 μg/mL of RNase A at 37 °C for 30 min. Propidium iodide was then added to a final concentration of 50 μg/mL for DNA staining and 20,000 fixed cells were analyzed on a FACScalibur (Becton-Dickinson, San Jose, CA). Cell cycle distribution was analyzed using the Modifit's program (Becton-Dickinson).
18. 1 is the tumor volume at day 1. Mice weight and tumor volume were recorded until animals were sacrificed at 19 days. Animal experiments were performed under the permission according to institutional guidelines.